Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases

References

• Yoshida M. Amyotrophic lateral sclerosis with dementia: the clinicopathological spectrum. Neuropathology24(1), 87–102 (2004).
   PubMed Web of Science ®Google Scholar
• Brun A. Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch. Gerontol. Geriatr.6(3), 193–208 (1987).
   PubMed Web of Science ®Google Scholar
• Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Brück W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain125(Pt 10), 2202–2212 (2002).
   PubMed Web of Science ®Google Scholar
• Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the “common” neurologic disorders? Neurology68, 326–327 (2007).
   PubMed Web of Science ®Google Scholar
• Menken M. Alzheimer’s disease and the modified role of the neurologist in today’s healthcare environment. Neurology51, 61–64 (1998).
   PubMed Web of Science ®Google Scholar
• Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J. Neurol. Sci.11(3), 205–242 (1970).
   PubMed Web of Science ®Google Scholar
• Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann. Neurol.10(2), 184–192 (1981).
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995–1997: a population-based study. Neurology52(3), 504–509 (1999).
   PubMed Web of Science ®Google Scholar
• Strong M, Rosenfeld J. Amyotrophic lateral sclerosis: a review of current concepts. Amyotrophic Lateral Scler. Other Motor Neuron Disord.4, 136–143 (2003).
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology46(4), 907–911 (1996).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med.338(5), 278–285 (1998).
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Bruck W, Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann. Neurol.56(2), 308 (2004).
   PubMed Web of Science ®Google Scholar
• De Stefano N, Matthews PM, Fu L et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain121, 1469–1477 (1998).
   PubMed Web of Science ®Google Scholar
• Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain127, 1463–1478 (2004).
   PubMed Web of Science ®Google Scholar
• Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med.8, 431–440 (1989).
   PubMed Web of Science ®Google Scholar
• Blennow K, Hampel H. Cerebrospinal fluid markers for incipient Alzheimer’s disease. Lancet Neurol.2, 606–613 (2003).
   Google Scholar
• Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst. Rev.1, CD005593 (2006).
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev.1, CD001447 (2007).
   Google Scholar
• Blennow K. CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment. Expert Rev. Mol. Diagn.5(5), 661–672 (2005).
   PubMed Web of Science ®Google Scholar
• Blennow K, Wallin A, Häger O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol. Scand.88, 221–223 (1993).
   PubMed Web of Science ®Google Scholar
• Giovannoni G. Multiple sclerosis cerebrospinal fluid biomarkers. Dis. Markers22, 187–96 (2006).
   PubMed Web of Science ®Google Scholar
• Bowser R, Cudkowicz M, Kaddurah-Daouk R. Biomarkers for amyotrophic lateral sclerosis. Expert. Rev. Mol. Diagn.6, 387–398 (2006).
   PubMed Web of Science ®Google Scholar
• Zougman A, Pilch B, Podtelejnikov A et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J. Proteome Res.7(1), 386–399 (2008).
   PubMed Web of Science ®Google Scholar
• Felgenhauer K. Protein size and cerebrospinal fluid composition. Klin. Wochenschri.52, 1158–1164 (1974).
   PubMedGoogle Scholar
• Lewczuk P, Reiber H, Tumani H. Intercellular adhesion molecule-1 in cerebrospinal fluid – the evaluation of blood-derived and brain-derived fractions in neurological diseases. J. Neuroimmunol.87(1–2), 156–161 (1998).
   PubMed Web of Science ®Google Scholar
• Widl K, Brettschneider J, Schattauer D et al. Erythropoietin in cerebrospinal fluid: age-related reference values and relevance in neurological disease. Neurochem. Res.32(7), 1163–1168 (2007).
   PubMed Web of Science ®Google Scholar
• Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand. J. Clin. Lab. Invest.37(5), 397–401 (1977).
   PubMed Web of Science ®Google Scholar
• Reiber H, Felgenhauer K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin. Chim. Acta163(3), 319–328 (1987).
   PubMed Web of Science ®Google Scholar
• Tourtellotte WW, Potvin AR, Fleming JO et al. Multiple sclerosis: measurement and validation of central nervous system IgG synthesis rate. Neurology30(3), 240–244 (1980).
   PubMed Web of Science ®Google Scholar
• Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta310(2), 173–186 (2001).
   PubMed Web of Science ®Google Scholar
• Felgenhauer K, Beuche W. Labordiagnostik neurologischer Erkrankungen. Thieme, Stuttgart, Germany, 24–27 (2007).
   Google Scholar
• Nilsson C, Stahlberg F, Thomsen C, Henriksen O, Herning M, Owman C. Circadian variation in human cerebrospinal fluid production measured by magnetic resonance imaging. Am. J. Physiol.262, 20–24 (1992).
   PubMed Web of Science ®Google Scholar
• Tumani H, Shen G, Peter JB, Bruck W. Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer disease? Arch. Neurol.56(10), 1241–1246 (1999).
   PubMedGoogle Scholar
• Buée L, Bussiere T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev.33, 95–130 (2000).
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J.8(2), 393–399 (1989).
   PubMed Web of Science ®Google Scholar
• Iqbal K, Alonso AD, Gondal JA et al. Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. J. Neural. Transm.59, 213–222 (2000).
   Google Scholar
• Vandermeeren M, Mercken M, Vanmechelen E et al. Detection of tau proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem.61, 1828–1834 (1993).
   PubMed Web of Science ®Google Scholar
• Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol.26(3), 231–245 (1995).
   PubMedGoogle Scholar
• Vigo-Pelfrey C, Seubert P, Barbour R et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer’s disease. Neurology45(4), 788–793 (1995).
   PubMed Web of Science ®Google Scholar
• Mori H, Hosoda K, Matsubara E et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci. Lett.186(2–3), 181–183 (1995).
   PubMed Web of Science ®Google Scholar
• Otto M, Wiltfang J, Tumani H et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeld-Jakob disease. Neurosci. Lett.225, 210–212 (1997).
   PubMed Web of Science ®Google Scholar
• Otto M, Wiltfang J, Cepek L et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology58(2), 192–197 (2002).
   PubMed Web of Science ®Google Scholar
• Grossman M, Farmer J, Leight S et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann. Neurol.57, 721–729 (2005).
   PubMed Web of Science ®Google Scholar
• Sjögren M, Davidsson P, Tullberg M et al. Both total and phosphorylated tau are increased in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry70, 624–630 (2001).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Minthon L, Clarberg A et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology53(7), 1488–1494 (1999).
   PubMed Web of Science ®Google Scholar
• Shoji M, Matsubara E, Kanai M et al. Combination assay of CSF tau, A β 1-40 and A β 1-42(43) as a biochemical marker of Alzheimer’s disease. J. Neurol. Sci.158(2), 134–140 (1998).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Diagnostic accuracy of Alzheimer’s disease: a clinicopathological study. Acta Neuropathol.91, 219–220 (1996).
   PubMed Web of Science ®Google Scholar
• Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer’s disease. Neurosci. Lett.259, 133–135 (1999).
   PubMed Web of Science ®Google Scholar
• Gómez-Tortosa E, Gonzalo I, Fanjul S et al. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch. Neurol.60(9), 1218–1222 (2003).
   PubMedGoogle Scholar
• Arai H, Terajima M, Miura M et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer’s disease. Ann. Neurol.38(4), 649–652 (1995).
   PubMed Web of Science ®Google Scholar
• Riemenschneider M, Wagenpfeil S, Vanderstichele H et al. Phospho-tau/total-tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias. Mol. Psychiatry8, 343–347 (2003).
   PubMed Web of Science ®Google Scholar
• Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol.5(3), 228–234 (2006).
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Petzold A, Süssmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology66(6), 852–856 (2006).
   PubMed Web of Science ®Google Scholar
• Sussmuth SD, Tumani H, Ecker D, Ludolph AC. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 β in cerebrospinal fluid and creatine kinase in serum. Neurosci. Lett.353, 57–60 (2003).
   PubMed Web of Science ®Google Scholar
• Kapaki E, Paraskevas GP, Michalopoulou M, Kilidireas K. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur. Neurol.43, 228–232 (2000).
   PubMed Web of Science ®Google Scholar
• Jimenez-Jimenez FJ, Hernanz A, Medina-Acebron S et al. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol. Scand.111, 114–117 (2005).
   PubMed Web of Science ®Google Scholar
• Sjögren M, Davidsson P, Wallin A et al. Decreased CSF-β-amyloid 42 in Alzheimer’s disease and amyotrophic lateral sclerosis may reflect mismetabolism of β-amyloid induced by disparate mechanisms. Dement. Geriatr. Cogn. Disord.13(2), 112–118 (2002).
   PubMed Web of Science ®Google Scholar
• Süssmuth SD, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): a blood–CSF barrier related evaluation in patients with various neurological diseases. Neurosci. Lett.300(2), 95–98 (2001).
   PubMed Web of Science ®Google Scholar
• Bartosik-Psujek H, Archelos JJ. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J. Neurol.251(4), 414–420 (2004).
   PubMed Web of Science ®Google Scholar
• Bartosik-Psujek H, Stelmasiak Z. The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosis. J. Neural. Transm.113(3), 339–345 (2006).
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Maier M, Arda S et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult. Scler.11(3), 261–265 (2005).
   PubMed Web of Science ®Google Scholar
• Terzi M, Birinci A, Cetinkaya E, Onar MK. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis. Acta Neurol. Scand.115(5), 325–330 (2007).
   PubMed Web of Science ®Google Scholar
• Guimarães I, Cardoso MI, Sá MJ. Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult. Scler.12(3), 354–356 (2006).
   PubMed Web of Science ®Google Scholar
• Jiménez-Jiménez FJ, Zurdo JM, Hernanz A et al. Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol. Scand.106(6), 351–354 (2002).
   PubMed Web of Science ®Google Scholar
• Martinez-Yelamos A, Rovira A, Sanchez-Valle R et al. CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS. J. Neurol.251(10), 1278–1279 (2004).
   PubMed Web of Science ®Google Scholar
• Brex PA, Gomez-Anson B, Parker GJ et al. Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. J. Neurol. Sci.166(1), 16–22 (1999).
   PubMed Web of Science ®Google Scholar
• Buerger K, Otto M, Teipel SJ et al. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol. Aging27(1), 10–15 (2006).
   PubMed Web of Science ®Google Scholar
• Vanmechelen E, Vanderstichele H, Davidsson P et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett.285, 49–52 (2000).
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Trenkwalder C, von Ahsen N et al. β-amlyoid 1–42 and tau-protein in cerebrospinal fluid of patients with Parkinson’s disease dementia. Dement. Geriatr. Cogn. Disord.22(3), 200–208 (2006).
   PubMed Web of Science ®Google Scholar
• Herukka SK, Hallikainen M, Soininen H, Pirttilä T. CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology64(7), 1294–1297 (2005).
   PubMed Web of Science ®Google Scholar
• Ewers M, Buerger K, Teipel SJ et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology69(24), 2205–2212 (2007).
   PubMed Web of Science ®Google Scholar
• Hampel H, Buerger K, Zinkowski R et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry.61(1), 95–102 (2004).
   PubMed Web of Science ®Google Scholar
• Petzold A, Keir G, Green AJ et al. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J. Immunol. Methods278, 179–190 (2003).
   PubMed Web of Science ®Google Scholar
• Barry DM, Millecamps S, Julien JP, Garcia ML. New movements in neurofilament transport, turnover and disease. Exp. Cell Res.313(10), 2110–2120 (2007).
   PubMed Web of Science ®Google Scholar
• Munoz DG, Greene C, Perl DP, Selkoe DJ. Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. J. Neuropathol. Exp. Neurol.47, 9–18 (1988).
   PubMed Web of Science ®Google Scholar
• Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem.67, 2013–2018 (1996).
   PubMed Web of Science ®Google Scholar
• Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur. J. Neurol.14(12), 1329–1333 (2007).
   PubMed Web of Science ®Google Scholar
• Goldstein ME, Sternberger NH, Sternberger LA. Phosphorylation protects neurofilaments against proteolysis. J. Neuroimmunol.14, 149–160 (1987).
   PubMed Web of Science ®Google Scholar
• Sternberger NH, Sternberger LA, Ulrich J. Aberrant neurofilament phosphorylation in Alzheimer disease. Proc. Natl Acad. Sci. USA82(12), 4274–4276 (1985).
   PubMed Web of Science ®Google Scholar
• Su JH, Cummings BJ, Cotman CW. Plaque biogenesis in brain aging and Alzheimer’s disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Brain Res.739(1–2), 79–87 (1996).
   PubMed Web of Science ®Google Scholar
• Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res.987, 25–31 (2003).
   PubMed Web of Science ®Google Scholar
• Rosengren LE, Karlsson JE, Sjögren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology52(5), 1090–1093 (1999).
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Petzold A, Schottle D, Claus A, Riepe M, Tumani H. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.21(5–6), 291–295 (2006).
   PubMed Web of Science ®Google Scholar
• Pijnenburg YA, Janssen JC, Schoonenboom NS et al. CSF neurofilaments in frontotemporal dementia compared with early onset Alheimer’s disease and controls. Dement. Geriatr. Cogn. Disord.23(4), 225–230 (2007).
   PubMed Web of Science ®Google Scholar
• Sjögren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology54(10), 1960–1964 (2000).
   PubMed Web of Science ®Google Scholar
• Hu YY, He SS, Wang XC et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci. Lett.320(3), 156–160 (2002).
   PubMed Web of Science ®Google Scholar
• Petzold A, Keir G, Warren J, Fox N, Rossor MN. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener. Dis.4(2–3), 185–194 (2007).
   PubMed Web of Science ®Google Scholar
• Norgren N, Sundström P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology63(9), 1586–1590 (2004).
   PubMed Web of Science ®Google Scholar
• Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry.64(3), 402–404 (1998).
   PubMed Web of Science ®Google Scholar
• Malmeström C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology61(12), 1720–1725 (2003).
   PubMed Web of Science ®Google Scholar
• Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J. Neuroimmunol.122(1–2), 132–139 (2002).
   PubMed Web of Science ®Google Scholar
• Petzold A, Eikelenboom MJ, Keir G et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J. Neurol. Neurosurg. Psychiatry76(2), 206–211 (2005).
   PubMed Web of Science ®Google Scholar
• Rejdak K, Petzold A, Stelmasiak Z, Giovannoni G. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult. Scler.14(1), 59–66 (2008).
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Petzold A, Junker A, Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult. Scler.12, 143–148 (2006).
   PubMed Web of Science ®Google Scholar
• Blennow K, Wallin A, Ekman R. Neuron specific enolase in cerebrospinal fluid: a biochemical marker for neuronal degeneration in dementia disorders? J. Neural. Transm. Park. Dis. Dement. Sect.8(3), 183–191 (1994).
   PubMedGoogle Scholar
• Infante JR, Martínez A, Ochoa J et al. Level of S-100 and neuron-specific enolase in cerebrospinal fluid from subjects with neurological pathologies. Rev. Esp. Med. Nucl.22(4), 238–243 (2003).
   PubMedGoogle Scholar
• Parnetti L, Palumbo B, Cardinali L et al. Cerebrospinal fluid neuron-specific enolase in Alzheimer’s disease and vascular dementia. Neurosci. Lett.183(1–2), 43–45 (1995).
   PubMed Web of Science ®Google Scholar
• Nooijen PT, Schoonderwaldt HC, Wevers RA, Hommes OR, Lamers KJ. Neuron-specific enolase, S-100 protein, myelin basic protein and lactate in CSF in dementia. Dement. Geriatr. Cogn. Disord.8(3), 169–173 (1997).
   PubMed Web of Science ®Google Scholar
• Cutler NR, Kay AD, Marangos PJ, Burg C. Cerebrospinal fluid neuron-specific enolase is reduced in Alzheimer’s disease. Arch. Neurol.43(2), 153–154 (1986).
   PubMedGoogle Scholar
• Zerr I, Bodemer M, Räcker S et al. Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt–Jakob disease. Lancet345(8965), 1609–1610 (1995).
   PubMed Web of Science ®Google Scholar
• Aksamit AJ Jr, Preissner CM, Homburger HA. Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt-Jakob disease. Neurology57(4),728–730 (2001).
   PubMed Web of Science ®Google Scholar
• Kropp S, Zerr I, Schulz-Schaeffer WJ et al. Increase of neuron-specific enolase in patients with Creutzfeldt–Jakob disease. Neurosci. Lett.261(1–2), 124–126 (1999).
   PubMed Web of Science ®Google Scholar
• Beaudry P, Cohen P, Brandel JP et al. 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease. Dement. Geriatr. Cogn. Disord.10(1), 40–46 (1999).
   PubMed Web of Science ®Google Scholar
• Lamers KJ, van Engelen BG, Gabreels FJ, Hommes OR, Borm GF, Wevers RA. Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurol. Scand.92(3), 247–251 (1995).
   PubMed Web of Science ®Google Scholar
• Royds JA, Davies-Jones GA, Lewtas NA, Timperley WR, Taylor CB. Enolase isoenzymes in the cerebrospinal fluid of patients with diseases of the nervous system. J. Neurol. Neurosurg. Psychiatry.46(11), 1031–1036 (1983).
   PubMed Web of Science ®Google Scholar
• Gmitterová K, Heinemann U, Bodemer M et al. 14-3-3 CSF levels in sporadic Creutzfeldt–Jakob disease differ across molecular subtypes. Neurobiol. Aging (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Wiltfang J, Otto M, Baxter HC et al. Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J. Neurochem.73(6), 2485–2490 (1999).
   PubMed Web of Science ®Google Scholar
• Martinez-Yelamos A, Saiz A, Sanchez-Valle R et al. 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology57(4), 722–724 (2001).
   PubMed Web of Science ®Google Scholar
• Colucci M, Roccatagliata L, Capello E et al. The 14-3-3 protein in multiple sclerosis: a marker of disease severity. Mult. Scler.10(5), 477–481 (2004).
   PubMed Web of Science ®Google Scholar
• de Seze J, Peoc’h K, Ferriby D, Stojkovic T, Laplanche JL, Vermersch P. 14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis. J. Neurol.249(5), 626–627 (2002).
   PubMed Web of Science ®Google Scholar
• Sánchez-Valle R, Saiz A, Graus F. 14-3-3 protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldt-Jakob disease. Neurosci. Lett.320(1–2), 69–72 (2002).
   PubMed Web of Science ®Google Scholar
• Jasperse B, Jakobs C, Eikelenboom MJ et al.N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. J. Neurol.254(5), 631–637 (2007).
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol.4(1), 32–41 (2005).
   PubMed Web of Science ®Google Scholar
• Fujita K, Honda M, Hayashi R et al. Transglutaminase activity in serum and cerebrospinal fluid in sporadic amyotrophic lateral sclerosis: a possible use as an indicator of extent of the motor neuron loss. J. Neurol. Sci.158(1), 53–57 (1998).
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Aschoff A, Niederwieser G, Heuberger C, Jirikowski G. Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer’s disease. Neurobiol. Dis.11(1), 106–110 (2002).
   PubMed Web of Science ®Google Scholar
• Vermes I, Steur EN, Jirikowski GF, Haanen C. Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson’s disease indicating apoptosis. Mov. Disord.19(10), 1252–1254 (2004).
   PubMed Web of Science ®Google Scholar
• Nemes Z, Fésüs L, Egerházi A, Keszthelyi A, Degrell IM. Nε(γ-glutamyl)lysine in cerebrospinal fluid marks Alzheimer type and vascular dementia. Neurobiol. Aging22(3), 403–406 (2001).
   PubMed Web of Science ®Google Scholar
• Jeitner TM, Bogdanov MB, Matson WR et al. Nε(γ-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington’s disease. J. Neurochem.79(5), 1109–1112 (2001).
   PubMed Web of Science ®Google Scholar
• Stoica BA, Movsesyan VA, Knoblach SM, Faden AI. Ceramide induces neuronal apoptosis through mitogen-activated protein kinases and causes release of multiple mitochondrial proteins. Mol. Cell. Neurosci.29(3), 355–371 (2005).
   PubMed Web of Science ®Google Scholar
• Malaplate-Armand C, Florent-Béchard S, Youssef I et al. Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol. Dis.23(1), 178–189 (2006).
   PubMed Web of Science ®Google Scholar
• Han X. Lipid alterations in the earliest clinically recognizable stage of Alzheimer’s disease: implication of the role of lipids in the pathogenesis of Alzheimer’s disease. Curr. Alzheimer Res.2(1), 65–77 (2005).
   PubMedGoogle Scholar
• Wang G, Silva J, Dasgupta S, Bieberich E. Long-chain ceramide is elevated in presenilin 1 (PS1M146V) mouse brain and induces apoptosis in PS1 astrocytes. Glia56(4), 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Satoi H, Tomimoto H, Ohtani R et al. Astroglial expression of ceramide in Alzheimer’s disease brains: a role during neuronal apoptosis. Neuroscience130(3), 657–666 (2005).
   PubMed Web of Science ®Google Scholar
• D’Souza SD, Bonetti B, Balasingam V et al. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J. Exp. Med.184(6), 2361–2370 (1996).
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci.27, 723–749 (2004).
   PubMed Web of Science ®Google Scholar
• Sen J, Belli A. S100B in neuropathologic states: the CRP of the brain? J. Neurosci. Res.85(7), 1373–1380 (2007).
   PubMed Web of Science ®Google Scholar
• Ozawa K, Suchanek G, Breitschopf H et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain117, 1311–1322 (1994).
   PubMed Web of Science ®Google Scholar
• Petzold A, Jenkins R, Watt HC et al. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer’s disease. Neurosci. Lett.336(3), 167–170 (2003).
   PubMed Web of Science ®Google Scholar
• Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer’s disease. Neurochem. Int.39(5–6), 409–413 (2001).
   PubMed Web of Science ®Google Scholar
• Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Increased S100β in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci. Lett.235(1–2), 5–8 (1997).
   PubMed Web of Science ®Google Scholar
• Fukuyama R, Izumoto T, Fushiki S. The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer’s disease patients and correlates with severity of dementia. Eur. Neurol.46(1), 35–38 (2001).
   PubMed Web of Science ®Google Scholar
• Crols R, Saerens J, Noppe M, Lowenthal A. Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer’s disease and other types of irreversible chronic organic brain syndrome. J. Neurol.233(3), 157–160 (1986).
   PubMed Web of Science ®Google Scholar
• Albrechtsen M, Sørensen PS, Gjerris F, Bock E. High cerebrospinal fluid concentration of glial fibrillary acidic protein (GFAP) in patients with normal pressure hydrocephalus. J. Neurol. Sci.70(3), 269–274 (1985).
   PubMed Web of Science ®Google Scholar
• Massaro AR, Michetti F, Laudisio A, Bergonzi P. Myelin basic protein and S-100 antigen in cerebrospinal fluid of patients with multiple sclerosis in the acute phase. Ital. J. Neurol. Sci.6(1), 53–56 (1985).
   PubMedGoogle Scholar
• Petzold A, Eikelenboom MJ, Gveric D et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain125, 1462–1473 (2002).
   PubMed Web of Science ®Google Scholar
• Lim ET, Grant D, Pashenkov M et al. Cerebrospinal fluid levels of brain specific proteins in optic neuritis. Mult. Scler.10(3), 261–265 (2004).
   PubMed Web of Science ®Google Scholar
• Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J. Neurol. Sci.133(1–2), 61–65 (1995).
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Scheltens P. Use of proteomic approaches to identify disease biomarkers. Lancet Neurol.6(12), 1036–1037 (2007).
   PubMed Web of Science ®Google Scholar
• Carrette O, Demalte I, Scherl A et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics3(8), 1486–1494 (2003).
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Williams E, Ganchev P et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J. Neurochem.95, 1461–1471 (2005).
   PubMed Web of Science ®Google Scholar
• Pasinetti GM, Ungar LH, Lange DJ et al. Identification of potential CSF biomarkers in ALS. Neurology66, 1218–1222 (2006).
   PubMed Web of Science ®Google Scholar
• Lehmensiek V, Süssmuth SD, Tauscher G et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult. Scler.13(7), 840–849 (2007).
   PubMed Web of Science ®Google Scholar
• Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer’s disease. Brain Res. Mol. Brain Res.118(1–2), 140–146 (2003).
   PubMedGoogle Scholar
• Jiménez CR, Koel-Simmelink MJA, Pham T, Teunissen CE. Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry. Proteomics Clin. Appl.1, 1385–1392 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang J, Goodlett DR, Quinn JF et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis.7(2), 125–133 (2005).
   PubMed Web of Science ®Google Scholar
• Yi EC, Marelli M, Lee H et al. Approaching complete peroxisome characterization by gas-phase fractionation. Electrophoresis23(18), 3205–3216 (2002).
   PubMed Web of Science ®Google Scholar
• Hammack BN, Fung KY, Hunsucker SW et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult. Scler.10(3), 245–260 (2004).
   PubMed Web of Science ®Google Scholar
• Dumont D, Noben JP, Raus J, Stinissen P, Robben J. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics4(7), 2117–2124 (2004).
   PubMed Web of Science ®Google Scholar
• Bossuyt PM, Reitsma JB, Bruns DE et al. Standards for Reporting of Diagnostic Accuracy. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin. Chem.49, 7–18 (2003).
   PubMed Web of Science ®Google Scholar
• Brazma A, Hingamp P, Quackenbush J et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet.29, 365–371 (2001).
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer93, 387–391 (2005).
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Appel RD, Van Eyk JE et al. Guidelines for the next 10 years of proteomics. Proteomics6, 4–8 (2006).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Vanmechelen E, van De Voorde A et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow-up study. J. Neurol. Neurosurg. Psychiatry64, 298–305 (1998).
   PubMed Web of Science ®Google Scholar
• Vanderstichele H, De Vreese K, Blennow K et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer’s disease and dementia with Lewy bodies. Clin. Chem. Lab. Med.44(12), 1472–1480 (2006).
   PubMed Web of Science ®Google Scholar
• Buerger K, Teipel SJ, Zinkowski R et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology59, 627–629 (2002).
   PubMed Web of Science ®Google Scholar
• Merched A, Serot JM, Visvikis S, Aguillon D, Faure G, Siest G. Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer’s patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett.425(2), 225–228 (1998).
   PubMed Web of Science ®Google Scholar
• Infante JR, Martínez A, Ochoa J et al. Cerebrospinal fluid S-100 protein levels in neurological pathologies. J. Physiol. Biochem.59(4), 255–261 (2003).
   PubMed Web of Science ®Google Scholar
• Davidsson P, Sjögren M, Andreasen N et al. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res. Mol. Brain Res.109(1–2), 128–133 (2002).
   PubMedGoogle Scholar
• Davidsson P, Westman-Brinkmalm A, Nilsson CL et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport13(5), 611–615 (2002).
   PubMed Web of Science ®Google Scholar